Kentaro Ide

Kentaro Ide

Auto-generated profile, based on publicly available information

Kentaro Ide

Graduate School of Biomedical and Health Sciences, Hiroshima University Department of Gastroenterological and Transplant Surgery Hiroshima

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2012 in Surgery Today
Verified
Journal Article
Closed access
PDF file
YSYoshihiro Saeki
Yoshihiro Saeki
KIKentaro Ide
Kentaro Ide
HKHideaki Kakizawa
Hideaki Kakizawa
MIMasaki Ishikawa
Masaki Ishikawa
HTHirotaka Tashiro
Hirotaka Tashiro
HOHideki Ohdan
Hideki Ohdan

1 June 2015 in Transplantation Direct
Verified
Journal Article
Open access
KIKentaro Ide
Kentaro Ide
YTYuka Tanaka
Yuka Tanaka
YSYu Sasaki
Yu Sasaki
HTHiroyuki Tahara
Hiroyuki Tahara
MOMasahiro Ohira
Masahiro Ohira
HOHideki Ohdan
Hideki Ohdan
Background Desensitization protocols comprising plasmapheresis, IVIGs, and rituximab and/or bortezomib have allowed for successful kidney transplantation in some highly HLA-sensitized patients with end-stage renal disease. However, the optimal combination of these therapies and their proper timing remains entirely unknown. We propose a phased desensitization strategy using rituximab followed by bortezomib as a safer method. Methods Three sensitized kidney transplant candidates who could not be desensitized using our conventional protocol, which consists of a single rituximab dose combined with plasmapheresis, were enrolled in this study. When IgM+ CD27− naive B cells reappeared but IgM+ CD27+ memory B cells remained undetectable in their peripheral blood, the patients were treated with 1 cycle of bortezomib followed by plasmapheresis. Results After bortezomib treatment, patients' donor-specific anti-HLA antibodies (DSA) values were decreased, and cross-match tests were consistently negative. All 3 patients underwent living donor kidney transplantation. They showed immediate renal function, and both DSA and non-DSA were undetectable during the observation period. Neither antibody-mediated rejection nor severe acute cellular rejection was encountered in these patients after transplantation. Conclusions The present cases suggest that a phased use of rituximab and bortezomib can safely desensitize highly sensitized kidney transplant candidates.

1 June 2016 in Human Immunology
Verified
Journal Article
Open access
HMHiroshi Morimoto
Hiroshi Morimoto
KIKentaro Ide
Kentaro Ide
YTYuka Tanaka
Yuka Tanaka
KIKohei Ishiyama
Kohei Ishiyama
MOMasahiro Ohira
Masahiro Ohira
HOHideki Ohdan
Hideki Ohdan
A desensitization protocol with rituximab is currently widely used for kidney transplantation (KT) and liver transplantation (LT) across the ABO blood group-incompatible (ABO-I) barrier. However, it remains to be elucidated whether rituximab is equally effective for B-cell and T-cell immune responses in both KT and LT recipients. To clarify these effects of rituximab, we enrolled 46 KT and 77 LT recipients in this study. The proportion of peripheral blood B-cells was determined at the perioperative period. T-cell responses to allostimulation were evaluated by a mixed lymphocyte reaction (MLR) assay. One week after rituximab administration, peripheral B-cells became undetectable in ABO-I KT recipients but remained detectable in some of the ABO-I LT recipients; B-cells were undetectable in both groups by week 2. B-cells remained below the detection limit throughout the first year in the ABO-I KT recipients, whereas they reappeared in the periphery after 6months in the ABO-I LT recipients. There were no significant differences in alloreactive T-cell responses based on MLR analyses between ABO-I and ABO-compatible groups. This study indicates that rituximab has differing B-cell sensitivity between KT and LT recipients and a minimal effect on the alloreactive T-cell responses in KT and LT recipients.

5 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YTYoshifumi Teraoka
Yoshifumi Teraoka
KIKentaro Ide
Kentaro Ide
HMHiroshi Morimoto
Hiroshi Morimoto
HTHiroyuki Tahara
Hiroyuki Tahara
HOHideki Ohdan
Hideki Ohdan
We have previously proven that the interspecies incompatibility of CD47 is responsible for in vitro phagocytosis of xenogeneic cells by host macrophages. Utilizing an in vivo model in the present study, we investigated whether genetically engineered expression of mouse CD47 in rat insulinoma cells (INS-1E) could inhibit macrophage-mediated xenograft rejection. INS-1E cells transfected with the pRc/CMV-mouse CD47 vector (mCD47-INS-1E) induced SIRPα-tyrosine phosphorylation in mouse macrophages in vitro, whereas cells transfected with the control vector (cont-INS-1E) did not. When these cells were injected into the peritoneal cavity of streptozotocin-induced diabetic Rag2−/−γ chain −/− mice, which lack T, B, and NK cells, the expression of mouse CD47 on the INS-1E cells markedly reduced the susceptibility of these cells to phagocytosis by macrophages. Moreover, these mice became normoglycemic after receiving mCD47-INS-1E, whereas the mice that received cont-INS-1E failed to achieve normoglycemia. Furthermore, injection of an anti-mouse SIRPα blocking monoclonal antibody into the mouse recipients of mCD47-INS-1E cells prevented achievement of normoglycemia. These results demonstrate that interspecies incompatibility of CD47 significantly contributes to in vivo rejection of xenogeneic cells by macrophages. Thus, genetic induction of the expression of recipient CD47 on xenogeneic donor cells could provide inhibitory signals to recipient macrophages via SIPRα; this constitutes a novel approach for preventing macrophage-mediated xenograft rejection.

26 July 2021 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
KOKosuke Ono
Kosuke Ono
KIKentaro Ide
Kentaro Ide
YTYuka Tanaka
Yuka Tanaka
MOMasahiro Ohira
Masahiro Ohira
HTHiroyuki Tahara
Hiroyuki Tahara
HOHideki Ohdan
Hideki Ohdan

26 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NTNaoki Tanimine
Naoki Tanimine
MOMasahiro Ohira
Masahiro Ohira
EKEmi Kurita
Emi Kurita
RNRyosuke Nakano
Ryosuke Nakano
HSHiroshi Sakai
Hiroshi Sakai
HOHideki Ohdan
Hideki Ohdan
Natural killer (NK) cells have immunosurveillance potential in hepatocellular carcinoma (HCC). We performed adaptive immunotherapy using donor-liver-derived natural killer (NK) cells after living-donor liver transplantation (LDLT) to prevent HCC recurrence. Dominant inhibitory signals tightly regulate NK cell activity via human leukocyte antigen (HLA)-specific inhibitory receptors, such as killer immunoglobulin-like receptors (KIRs). The functional recognition of HLA through KIR raises the NK cell capacity, which is a process termed “licensing.” Here, we investigated the effect of polymorphic KIR-HLA genotypes on the efficacy of NK-cell-based immunotherapy after LDLT. Seventy-seven Japanese recipients with HCC who underwent LDLT and their corresponding donors between 1996 and 2016 were enrolled in this study. The median follow-up period was 8.3 years. The HCC recurrence risk was stratified using radiological and pathological assessments according to the Milan criteria. Of the 77 recipients, 38 received immunotherapy. Immunotherapy improves early post-transplantation survival and lowers the recurrence rate in the intermediate-risk recipients. We analyzed the genotypes of five inhibitory KIRs and HLA using sequence-specific polymorphism-based typing. The polymorphic KIR-HLA genotype revealed that genetically vulnerable liver transplant recipients with a poorly licensed NK genotype have an improved prognosis by immunotherapy with donor-liver-derived NK cells. Thus, the combination of recipient and donor KIR-HLA genotypes is worthy of attention for further investigation, especially considering the clinical application of NK-cell-based immunotherapy.